Recurrence of prostate cancer refers to the reappearance of detectable disease after initially successful definitive treatment. In many patients, the first indication is a renewed rise in serum prostate-specific antigen (PSA). Several distinct patterns of recurrence are recognised:
With contemporary imaging—particularly prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT)—and increasingly refined salvage-treatment strategies, recurrent disease can frequently be detected at an earlier stage and treated in a highly individualised, lesion-directed manner.
A biochemical recurrence does not automatically indicate immediately life-threatening disease. The natural history varies substantially according to tumour biology, PSA kinetics, pathological risk features, the interval from primary treatment to recurrence, and the presence or absence of radiographically detectable metastatic disease. Many patients remain free of clinically significant progression for years.
Following complete surgical removal of the prostate, serum PSA should fall to an undetectable or nearly undetectable level. A persistently detectable or subsequently rising PSA may indicate residual or recurrent prostate cancer.
Biochemical recurrence after radical prostatectomy is commonly defined as a PSA level of ≥0.2 ng/mL confirmed by a second measurement.
Following definitive radiotherapy, including stereotactic body radiotherapy (SBRT/CyberKnife) or brachytherapy, benign prostate tissue remains in situ. Consequently, PSA generally declines gradually over time rather than becoming undetectable.
Biochemical recurrence after radiotherapy is commonly defined according to the Phoenix definition as a PSA increase of ≥2 ng/mL above the lowest PSA level achieved after treatment—the PSA nadir.
Important: A transient post-radiotherapy increase in PSA, known as a PSA bounce, may occur and does not by itself constitute evidence of recurrent prostate cancer.
Salvage radiotherapy is directed to the prostate bed after radical prostatectomy in patients with biochemical or radiographically localised recurrence. Its purpose is to eradicate residual or recurrent microscopic or macroscopic tumour and thereby achieve durable disease control. Contemporary treatment planning may incorporate PSMA PET/CT and MRI findings, and selected patients may also require irradiation of regional pelvic lymphatics.
Androgen-deprivation therapy (ADT) suppresses androgen production and/or androgen-receptor signalling, thereby inhibiting a principal biological driver of prostate-cancer growth. ADT may be combined with salvage radiotherapy in patients with adverse risk features or used as systemic therapy when disease is not amenable to curative local salvage treatment (further treatment for cancer that has returned).
Image-guided irradiation of involved pelvic or extra-pelvic lymph nodes can be used to achieve local control of nodal metastatic disease. In selected patients with oligorecurrent nodal disease, metastasis-directed stereotactic radiotherapy may delay further systemic progression and the need for long-term systemic treatment.
Salvage radical prostatectomy is the surgical removal of the prostate after previous definitive radiotherapy in carefully selected patients with biopsy-confirmed, locally recurrent disease and no evidence of distant metastases. The aim is complete eradication of the local recurrence. Because previous irradiation alters tissue planes and healing characteristics, salvage prostatectomy is technically demanding and is associated with higher rates of urinary and other genitourinary complications than primary prostatectomy.
Salvage brachytherapy delivers a second course of highly localised radiation from radioactive sources positioned within or immediately adjacent to the recurrent intraprostatic tumour. The objective is to achieve a therapeutically effective dose within the recurrence while limiting additional radiation exposure to previously irradiated organs at risk, particularly the urethra, bladder, and rectum.
High-intensity focused ultrasound (HIFU) is a minimally invasive ablative technique in which convergent ultrasound energy generates focal thermal injury and coagulative necrosis within the targeted tumour tissue. In carefully selected patients, it may be considered for small, localised intraprostatic recurrences after radiotherapy.
Cryotherapy is an ablative salvage technique in which recurrent prostate-cancer tissue is exposed to controlled freeze–thaw cycles, producing irreversible cellular injury. It may be considered as an alternative local salvage treatment in selected patients with organ-confined recurrence after previous radiotherapy.
Focal re-irradiation uses contemporary high-precision radiation techniques—such as robotic CyberKnife stereotactic body radiotherapy—to deliver an additional ablative radiation dose selectively to the recurrent tumour. Precise target delineation and steep dose gradients are essential because the bladder, urethra, rectum, and surrounding tissues have already received radiation during the primary treatment course.
ADT remains a fundamental systemic treatment for recurrent metastatic prostate cancer. By markedly reducing circulating testosterone concentrations or blocking androgen signalling, it suppresses androgen-dependent tumour growth and can achieve substantial biochemical and clinical disease control.
Contemporary androgen-receptor pathway inhibitors provide more potent suppression of androgen signalling than conventional ADT alone. Depending on disease setting and prior therapy, these agents may be combined with ADT to prolong progression-free and overall survival.
Systemic cytotoxic chemotherapy targets proliferating cancer cells throughout the body and is an established component of treatment for selected patients with metastatic hormone-sensitive or castration-resistant prostate cancer, depending on disease burden, prior therapy, symptoms, and overall clinical status.
PSMA-targeted radioligand therapy is a molecularly targeted systemic treatment in which a therapeutic radionuclide is coupled to a ligand that binds prostate-specific membrane antigen expressed on prostate-cancer cells. This enables selective delivery of ionising radiation to PSMA-expressing tumour sites throughout the body while limiting exposure of non-target tissues.
Metastasis-directed radiotherapy, most commonly delivered as stereotactic body radiotherapy, selectively treats individual metastatic lesions with ablative radiation doses. In patients with oligometastatic or oligorecurrent disease, this approach may achieve durable local control, delay progression, postpone escalation of systemic therapy, and alleviate symptoms where present.
CyberKnife treatment may be considered both after radical prostatectomy and after previous definitive radiotherapy for prostate cancer, provided that the recurrent disease pattern, prior radiation exposure, anatomical relationships, and overall oncological situation permit a safe and meaningful local salvage approach.
Robotic image-guided treatment enables highly accurate target localisation and conformal dose delivery. When treating recurrent prostate cancer, particular attention is paid to minimising cumulative radiation exposure to critical organs at risk, including the urethra, urinary bladder, rectum, and adjacent bowel.
The non-invasive outpatient approach can reduce treatment burden and facilitate rapid return to normal daily activities in appropriately selected patients.
Prognosis is determined by the combined assessment of PSA kinetics, pathological grade, molecular and clinical tumour biology, site and extent of recurrence, response to previous therapy, and the patient's overall medical condition. A PSA rise alone does not define the clinical aggressiveness of recurrent disease.
Not every recurrence inevitably progresses to metastatic disease. The clinical significance of recurrent prostate cancer is determined less by the PSA increase in isolation than by the underlying tumour biology, the rate of biochemical progression, the interval from primary treatment to recurrence, and the presence or absence of metastatic disease. Modern molecular imaging, particularly PSMA PET/CT, can identify recurrent disease at substantially lower tumour burdens than was previously possible and may enable more precisely targeted salvage treatment.
A biochemical recurrence is generally not a medical emergency. Nevertheless, a confirmed renewed PSA rise should be evaluated promptly by a specialist prostate-cancer team. The optimal strategy depends on the estimated biological risk, PSA kinetics, prior treatment, imaging findings, and the anatomical extent of recurrent disease. In selected patients, careful surveillance may be appropriate; in others, early salvage treatment offers the greatest probability of durable disease control.
More timely intervention should be considered when PSA rises rapidly, the PSA doubling time is short—for example, less than approximately 9–12 months—metastatic disease is demonstrated, high-grade tumour biology is present (e.g. Gleason score 8–10 / ISUP Grade Groups 4–5), or imaging identifies a localised recurrence that remains amenable to potentially curative salvage treatment.
Request a no-obligation review of your medical reports by our medical team.